All News
ACR Position Statements on Drug Pricing and Step Therapy
The American College of Rheumatology Committee on Rheumatologic Care has released new drug pricing and step therapy position statements that they hope legislators will consider as they continue to explore policy and regulatory options to make drugs more affordable and accessible.
Read Article
Increasing Prevalence and Consequences of Interstitial Lung Disease in RA
Interstitial lung disease (ILD) has been a hot topic in numerous journals recently with reports of increasing incidence and links to disease activity.
Read Article
Data from the Osteoarthritis Initiative (n 4369) shows that fluctuating or persistent Knee pain over 1 yr had an increased risk of cartilage volume loss and structural progression over 4 years (OR 1.62, 95% CI 1.04–2.54) https://t.co/Inf4WsQ4Lz
Links:
Dr. John Cush RheumNow ( View Tweet)
17.6 million adult Americans, 1 of 12, have an alcohol-use disorder, according to the National Council on Alcoholism and Drug Dependence. https://t.co/duojLFsNjD
Links:
Dr. John Cush RheumNow ( View Tweet)
Analysis of CareRA, early RA 330 pt trial shows long term outcomes linked to initial response type rather than regimen. Best PROMs in the 42% with early persistent response. 9% were primary NR, 28% secondary NR, 21% delayed responders. https://t.co/ZDqYD3krtb
Links:
Dr. John Cush RheumNow ( View Tweet)
Long term safety study of 4481 tofacitinib pts w/ 9.5yrs exposure (16,291PYs). 52% discontinued Rx (4% insufficient response; 24% adverse events). AE incidence rates were 3.4/100PY for H zoster, 2.4/100Py SIE, 0.8 cancer, 0.4 MACE, 0.3 Mortality. https://t.co/Qv5keuKXr3
Links:
Dr. John Cush RheumNow ( View Tweet)
41 study Metanalysis on H zoster drug risk in psoriasis and PsA - finds an increased risk w/ steroids, tofacitinib, biologic +DMARD Combination Rx. But no risk with monotherapy. Insufficient evidence for IL-12/23, -7, -23 inhibitors or apremilast https://t.co/KRrTqIw7Ko
Links:
Dr. John Cush RheumNow ( View Tweet)
NSAIDS can reduce fertility in women - from Dr Sammaritano. #RNL2019
Madelaine Feldman MattieRheumMD ( View Tweet)
#RNL2019 But ANCA wont completely replace it. (depends on scenario) --Dr Langford https://t.co/rygxJ2EVFR
L rheumarhyme ( View Tweet)
Do female vs. male patients with AS #spondyloarthritis present differently? Dr Husni #RNL2019 https://t.co/ZEGuRzxGUn
MedR #QuedateEnCasa MedReuma ( View Tweet)
Dr Craig Leonardi's review of Effective biologics to achieve a PASI 100 in Psoriasis. The newer agents are far ahead! #RNL2019 https://t.co/p71hb58SAf
Dr. John Cush RheumNow ( View Tweet)
Dining neath the stars with some of my favorite rheumatologists at RheumNow Live @LCalabreseDO @McknightmdEllen #RNL2019 https://t.co/bMNeeyMrf8
Madelaine Feldman MattieRheumMD ( View Tweet)
2016 ASAS-EULAR treatment recommendations for axSpA Dr Ruderman #Spondylitis #RNL2019 https://t.co/NtIPbryT5y
MedR #QuedateEnCasa MedReuma ( View Tweet)
Reminder on dosing of tocilizumab in GCA #rnl2019 https://t.co/SbExbhfEGg
caocosm caocosm ( View Tweet)
Updates to ASAS guidelines #rnl2019 Dr Ruderman https://t.co/pkoGhToY99
k dao KDAO2011 ( View Tweet)
Important point! - Many patients with SpA may have FMS - BUT - FMS patients don't meet SpA criteria. - Dr Eric Ruderman @JointMD #rnl2019 https://t.co/aDIpgX8Ihj
caocosm caocosm ( View Tweet)
#RNL2019 Dr Carol Langford discusses when to use RTX vs CTX in GPA https://t.co/w0vWVrf7JX
Dr. John Cush RheumNow ( View Tweet)
In newly Dx GPA it’s ok to treat with steroids PLUS MTX or MMF or RTX. #RNL2019 Dr Carol Langford https://t.co/rihhR6x7u3
Dr. John Cush RheumNow ( View Tweet)
Distinguishing b/t AS and nonradiographic SpA (AS more likely to be males; higher CRP); nonradiographic SpA more likely female; more have FM symptoms; lower CRP Dr E Ruderman #rnl2019 https://t.co/wb7WuPAoUF
k dao KDAO2011 ( View Tweet)
Erdheim Chester dz as a mimic of vasculitis or IgG4 related disease. Pearls from #RNL2019 Dr. Philip Seo https://t.co/TPuLfwG5Ye
Dr. John Cush RheumNow ( View Tweet)